These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26258832)

  • 1. Waiting for the Antidote: The Journey of Idarucizumab as a Potential Specific Reversal Agent for Dabigatran (Pradaxa).
    O'Malley PA
    Clin Nurse Spec; 2015; 29(5):262-4; quiz E8. PubMed ID: 26258832
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
    Giustozzi M; Verso M; Agnelli G; Becattini C
    J Thromb Thrombolysis; 2017 Nov; 44(4):527-535. PubMed ID: 28913672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Administration of idarucizumab in spontaneous intracerebral hemorrhage under dabigatran-therapy].
    Bereczki D; Szilágyi G; Kakuk I; Szakács Z; May Z
    Ideggyogy Sz; 2017 Sep; 70(9-10):349-353. PubMed ID: 29870627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Systemic thrombolysis after the administration of idarucizumab in acute ischemic stroke].
    Pásztor M; Bereczki D; Szakács Z; May Z
    Ideggyogy Sz; 2017 Jul; 70(7-8):284-288. PubMed ID: 29870643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [First NOAk specific antidote as additional safety factor in therapy].
    MMW Fortschr Med; 2016 Feb; 158(2):66-7. PubMed ID: 27017635
    [No Abstract]   [Full Text] [Related]  

  • 6. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
    Miyares MA; Kuyumjian Y; Eaves S; Dollard E
    J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concerns about idarucizumab for dabigatran reversal.
    Stöllberger C; Pommer P; Schneider B; Finsterer J
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):473-4. PubMed ID: 27124105
    [No Abstract]   [Full Text] [Related]  

  • 8. Idarucizumab (Praxbind) for Dabigatran (Pradaxa) Anticoagulant Reversal.
    Jarrett JB; Gimbar RP
    Am Fam Physician; 2017 Jun; 95(12):798-800. PubMed ID: 28671421
    [No Abstract]   [Full Text] [Related]  

  • 9. Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant.
    Finks SW; Rogers KC
    Am J Med; 2017 May; 130(5):e195-e197. PubMed ID: 28011314
    [No Abstract]   [Full Text] [Related]  

  • 10. Idarucizumab for Reversal of Dabigatran in Early/Emergency Surgeries: A Case Series.
    Peacock WF; Grotta JC; Steiner T
    J Emerg Med; 2019 Dec; 57(6):e167-e173. PubMed ID: 31662218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards the development of specific antidotes: Idarucizumab for reversal of dabigatran effects.
    Hobl EL; Jilma B
    Thromb Haemost; 2015 Jun; 113(6):1162-3. PubMed ID: 25926042
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
    Glund S; Moschetti V; Norris S; Stangier J; Schmohl M; van Ryn J; Lang B; Ramael S; Reilly P
    Thromb Haemost; 2015 May; 113(5):943-51. PubMed ID: 25789661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
    Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
    Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Goal-directed administration of antidote for reversal of dabigatran anticoagulation].
    Lindeman E
    Lakartidningen; 2017 Dec; 114():. PubMed ID: 29292966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
    Boda Z
    Orv Hetil; 2016 Mar; 157(12):443-50. PubMed ID: 26971644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Antidote Is Finally Here! Idarucizumab, A Specific Reversal Agent for the Anticoagulant Effects of Dabigatran.
    O'Malley PA
    Clin Nurse Spec; 2016; 30(2):81-3; quiz E9. PubMed ID: 26848896
    [No Abstract]   [Full Text] [Related]  

  • 17. Structure-guided residence time optimization of a dabigatran reversal agent.
    Schiele F; van Ryn J; Litzenburger T; Ritter M; Seeliger D; Nar H
    MAbs; 2015; 7(5):871-80. PubMed ID: 26047352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal Agents for Direct Oral Anticoagulants: Understanding New and Upcoming Options.
    Rogers KC; Shelton MP; Finks SW
    Cardiol Rev; 2016; 24(6):310-315. PubMed ID: 27548686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?
    Miller L; Ferreira JA; Tucker C
    J Emerg Med; 2017 Mar; 52(3):341-347. PubMed ID: 27727040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idarucizumab: a quick and effective antidote administered prior to coronary artery bypass surgery and mitral valve annuloplasty in a patient treated with dabigatran.
    Sałacki AJ; Zapolski T; Wysokiński A
    Pol Arch Intern Med; 2017 Sep; 127(9):635-638. PubMed ID: 28724875
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.